梅州怎样修复修补处女膜(梅州怎样治疗中度宫颈炎) (今日更新中)

BEIJING, Oct. 26 (Xinhua) -- The central government allocated 935 million yuan (147 million U.S. dollars) Wednesday to areas hit by rain-triggered floods, the Ministry of Civil Affairs (MCA) said.The relief funds, jointly allocated by the MCA and the Ministry of Finance, will be used for disaster survivors to relocate, rebuild houses and buy daily necessities.The funds will also be delivered to the family members of the victims, according to the ministry.The funds will go to the flood-hit provinces of Shanxi, Henan, Hubei, Sichuan, Shanxi and Guangxi Zhuang Autonomous Region.The government already allocated 132 million yuan (20.6 million U.S. dollars) to disaster hit areas immediately after the floods happened in September.Rain-triggered floods and disasters left 97 people dead, 21 missing and 1.23 million affected in September in China's 11 provincial-level regions, and a total of 1.93 million people were relocated urgently to avoid further casualties.The disasters also caused an estimated 21 billion yuan (3.29 billion U.S. dollars) in direct economic losses, according to official data.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

SAN FRANCISCO, Nov. 7 (Xinhua) -- Google on Monday added a highly-anticipated service to its Google+ social network, allowing businesses and brands to set up their own pages on the site.Named "Google+ Page," the service is a further challenge to its rival Facebook's fan pages, which has become a major promotion strategy for many business brands over the past several years.Unlike Facebook, Google will not charge businesses and organizations for using the scheme, and will not put ads on the pages. The service is expected to enhance the tech giant's other businesses like search and mobile advertising.Some big brand names, such as Burberry, the Barcelona football club and the Muppets, have already set up their pages.Google noted it will not pass on personal data.In addition to big brands, Google also wants small businesses that have or do not have their own websites to use Google+ Pages as their default presences.According to a report by Ad Age Digital, Google+ Pages will soon be location-aware, allowing local businesses to send offers and deals to mobile phones.According to Google, more than 40 million people have opened an account with its social network, which was launched in June. Although the network is growing very quickly, some analysts said it still has a long way to go to become a major threat to Facebook, which has more than 800 million users.

BEIJING, Jan. 14 (Xinhua) -- China and member countries of the Association of Southeast Asian Nations (ASEAN) on Saturday held a meeting of senior officials on the implementation of the Declaration on the Conduct of Parties in South China Sea.All the participants had in-depth discussion and reached a series of consensus, said a press release posted on the Foreign Ministry's official website (www.fmprc.gov.cn).The meeting concluded that the general situation of South China Sea is peaceful and stable, and appreciated the positive efforts from all concerned sides.The meeting regarded 2011 as a fruitful year with positive progress made in implementing the declaration, and reached consensus on the future works, including to speed up specific cooperation projects, and to host seminars on maritime disaster-relief, environment, rescue and biology research.All the parties agreed to set up experts committees on maritime scientific research, environmental protection, security and rescue, and on the crackdown on cross-border crimes, and to better utilize the China-ASEAN fund on maritime cooperation.

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.

来源：资阳报